Results 141 to 150 of about 3,302 (197)

Filgotinib

Reactions Weekly
semanticscholar   +9 more sources

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.

The Lancet, 2021
BACKGROUND The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor ...
B. Feagan, S. Danese, E. Loftus, S. Vermeire, S. Schreiber, T. Ritter, R. Fogel, R. Mehta, S. Nijhawan, R. Kempiński, R. Filip, I. Hospodarskyy, U. Seidler, F. Seibold, I. Beales, Hyo Jong Kim, J. McNally, C. Yun, Sally Zhao, Xiaopeng Liu, C. Hsueh, Chantal Tasset, R. Besuyen, Mamoru Watanabe, W. Sandborn, G. Rogler, T. Hibi, L. Peyrin-Biroulet   +27 more
semanticscholar   +1 more source

Filgotinib as rheumatoid arthritis therapy

Drugs of Today, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini, E, Di Donato, D, Santilli, G, Lucchini, F, Mozzani, M, Riva, A, Ariani   +6 more
openaire   +2 more sources

Filgotinib in rheumatoid arthritis

Expert Review of Clinical Immunology, 2022
Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire   +2 more sources

The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease

Immunotherapy, 2023
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J, D'Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S   +11 more
openaire   +3 more sources

Filgotinib for moderately to severely active ulcerative colitis

Expert Review of Gastroenterology & Hepatology, 2022
Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese   +4 more
openaire   +2 more sources

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan

Alimentary Pharmacology and Therapeutics
While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real‐world studies assessing its short‐ and long‐term efficacy and safety are limited.
Shintaro Akiyama, K. Yokoyama, S. Yagi, S. Shinzaki, Kozo Tsuruta, S. Yoshioka, Minako Sako, Hiromichi Shimizu, Mariko Kobayashi, Toshiyuki Sakurai, Kei Nomura, T. Shibuya, M. Takahara, S. Hiraoka, Kyohei Sugai, S. Yanai, Atsushi Yoshida, M. Koroku, T. Omori, Masayuki Saruta, Takayuki Matsumoto, R. Okamoto, Kiichiro Tsuchiya, T. Fujii   +23 more
semanticscholar   +1 more source

Filgotinib Improves Experimental Pulmonary Fibrosis by Modulating JAK1/STAT3/SOCS3/IL‐17A Signalling

Basic & Clinical Pharmacology & Toxicology
Regulatory agencies in Europe and Japan have approved filgotinib, a selective JAK1 inhibitor, for use in treating rheumatoid arthritis, but its effect and mechanism of action in treating pulmonary fibrosis remain unclear.
Yunying Lv, Guanghua Zhang, Dexin Kong, Wanglin Jiang   +3 more
semanticscholar   +1 more source

A Constant Filgotinib Delivery Adhesive Platform Based on Polyethylene Glycol (PEG) Hydrogel for Accelerating Wound Healing via Restoring Macrophage Mitochondrial Homeostasis.

Small
Skin wound healing is often hindered by disrupted mitochondrial homeostasis and imbalanced macrophage glucose metabolism, posing a critical challenge to improve patient outcomes.
Jian Xie, Yiqian Huang, Xiaofeng Hu, Xiaowei Wu, Xi Luo, Pengfei Wei, Wei Jing, Bo Zhao, Jiansheng Su   +8 more
semanticscholar   +1 more source

Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights

Expert Review of Clinical Pharmacology, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose natural course has been deeply modified thanks to the development of new therapeutic approaches. The Janus kinase inhibitors (Jakinibs) represent the newest class of drugs introduced for treating RA.
Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali, Ennio Giulio Favalli   +5 more
openaire   +2 more sources